Full Press Release Details
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors.
IDYA
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors
Key Takeaway: IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors